FOSUN HEALTH Logo

Multiple Myeloma FAQ

catalogue

Multiple Myeloma FAQ

Multiple Myeloma FAQ

The questions on this page come after the medical ones have been answered — what treatment will cost, how long the patient will be away from home, which drugs can actually be given here, and what happens on return. They are answered separately on purpose, because myeloma is treated continuously over years rather than in a single episode, and the practical arrangements are what make that possible to sustain.

What treatment costs

Treatment in China typically costs 30% to 50% of the equivalent in Europe or the United States. The total depends on which parts of the pathway you need:

  • Diagnosis and staging — the protein studies, the marrow examination with chromosome testing, and whole-skeleton imaging; modest individually, and the basis of everything that follows.
  • Induction treatment — the largest drug cost in the first year, since it combines three classes plus an antibody, and the total is counted in cycles rather than doses.
  • Stem cell collection and transplant — apheresis, cell processing and storage, the high-dose treatment, and several weeks of inpatient care with transfusion and anti-infective support.
  • Maintenance treatment — a lower cost per month but continued over years, which is why it is worth asking for the monthly figure rather than only the induction estimate.
  • Supportive treatment — bone-strengthening drugs, prophylaxis, growth factors and vaccinations; individually small, and a real part of the total over a long course.

How long you will need to stay

The length of a stay is determined by which phase of treatment you are in rather than by any general rule:

  • Initial assessment — usually one to two weeks, because the protein studies, the marrow examination and the chromosome testing need time to be reported.
  • Induction cycles — each cycle is given over a few days, with an interval of two to three weeks between cycles; many patients are treated as outpatients with short admissions rather than staying throughout.
  • Transplant — several weeks in hospital, covering the high-dose treatment and the period during which the blood counts are low, followed by outpatient monitoring before travel is considered.
  • Maintenance — no admission, since it is oral treatment taken at home with periodic blood tests, which many patients arrange locally.

Which medicines are available

Most medicines used in myeloma internationally are available here:

  • Proteasome inhibitors — including the first-generation drug and the later ones used in relapse, with one of them favoured when kidney function is impaired.
  • Immunomodulatory drugs — including the agent used as maintenance after transplant and the later generation used in relapsed disease.
  • Monoclonal antibodies directed at CD38 — used in the first line in combination, and again in later lines.
  • Bone-strengthening drugs — both the intravenous bisphosphonate and the alternative agent used when kidney function limits it.
  • Bispecific antibodies and CAR T-cell therapy directed at BCMA — available for disease that has returned after several lines, subject to an assessment of suitability.
  • Supportive medicines — infection prophylaxis, antivirals, growth factors, clot prevention and pain control; these are part of the regimen, not optional extras.

Sending records and receiving a written opinion

The most useful thing to send is the original documents rather than a summary:

  • The protein studies with their values and units — electrophoresis and immunofixation reports, and the free light chain ratio with both values, at each time point rather than only the most recent.
  • The marrow reports — the plasma cell proportion, the trephine description, and the FISH findings, since these set the risk group that affects how intensive treatment should be.
  • The imaging report — whole-body low-dose CT, MRI or PET-CT as performed, with the number and sites of lesions.
  • The treatment history — each combination given, the dates, the number of cycles, any dose reductions, and the response measured after each phase.
  • Recent blood results — the full blood count, calcium, creatinine and albumin, which determine what can be given safely now.

Insurance and payment

Coverage for myeloma needs checking in more detail than for most conditions, because treatment continues over years:

  • Check whether the policy covers treatment outside your country of residence before assuming it does, and whether prior authorisation is required for each phase.
  • Check the outpatient drug cover specifically — continuous oral treatment is often handled differently from inpatient care, and it is where the long-run cost sits.
  • Check the transplant provision, including cell collection, processing and storage, the admission itself, and the months of follow-up. These are frequently bundled or capped.
  • Ask whether direct billing is available for your insurer, and request the documentation they require at the outset — a plan, an estimate and clinical justification take time to assemble.

After treatment, and back home

Because myeloma is managed over years, the handover document matters more here than in most conditions:

  • A written summary of the treatment actually given — each drug, the cumulative dose, the cycles completed, and the response measured at the end of each phase.
  • A monitoring schedule with defined intervals — which tests, at what intervals, and what change would prompt an earlier review.
  • The prophylaxis plan — anti-infective medication, antivirals, clot prevention, and the vaccination schedule with the interval after treatment during which live vaccines are avoided.
  • Long-term points to monitor — kidney function, bone health including a dental review before and during bone-strengthening treatment, blood counts on continuous treatment, and second cancers, which occur rarely and are one reason review continues.
  • A named contact, for questions between visits and for a video review of results taken elsewhere.

Eating and daily life during treatment

No diet treats myeloma. What nutrition and daily life can do is support you through long-term treatment:

  • Food safety matters more than food choice. During periods when the white cell count is low, avoiding unpasteurised dairy, raw or undercooked meat, eggs and seafood, and unwashed produce is a concrete protective measure.
  • Adequate protein and calories to maintain weight, because weight loss affects how the next cycle is tolerated and because steroids can affect appetite and blood sugar.
  • Fluid intake — drinking enough protects the kidney, which is the organ most at risk in this disease, and it is particularly important during treatment and in hot weather.
  • Gentle activity and fall prevention — keeping muscles and balance working reduces fractures, while becoming inactive weakens both bone and muscle.
  • Supplements — discuss them with the team first, because some interact with treatment, and a supplement marketed as protecting bone does not replace the medicine prescribed for that purpose.

Frequently Asked Questions

How much does myeloma treatment cost in China?

Treatment in China typically costs 30% to 50% of the equivalent in Europe or the United States. The total depends on which phases you need: induction combines three drug classes plus an antibody and is the largest drug cost in the first year, a stem cell transplant adds several weeks of inpatient care with cell collection and processing, and maintenance treatment is a lower monthly cost continued over years. Supportive treatment adds a real but modest amount throughout. A formal itemised estimate is prepared from your own records and your proposed plan, and it is worth asking for the monthly figure for maintenance rather than only the induction estimate.

How long will I need to stay in China?

It depends on the phase. The initial assessment usually takes one to two weeks while the protein studies, marrow examination and chromosome testing are reported. Induction is given in cycles, each over a few days with two to three weeks between them, and many patients attend as outpatients with short admissions. Stem cell collection takes several days of injections plus one or two apheresis sessions. A transplant involves several weeks in hospital followed by outpatient monitoring before travel. Maintenance is oral treatment taken at home, which many patients arrange locally with periodic blood tests sent to us.

Are the same myeloma drugs available as in my own country?

Most are. Proteasome inhibitors including the later generation, immunomodulatory drugs including the one used as maintenance, antibodies directed at CD38, bone-strengthening drugs, and bispecific antibodies and CAR T-cell therapy directed at BCMA are all available in our network. Availability of a specific product depends on the hospital and the indication, so it should be confirmed in writing as part of the plan. If a particular agent is not available, ask what the realistic alternative is — in most cases it is a drug of the same class, and the substitution is a routine one.

What should I bring, and what should I take home?

Bring the protein measurements with values and units at each time point, the light chain ratio, the marrow reports including the FISH findings, the imaging report, the full treatment history with dates and responses, and recent blood and kidney results. Take home a written summary of the treatment actually given with cumulative doses, a monitoring schedule with defined intervals, the prophylaxis and vaccination plan, guidance on what to report between visits, and a named contact. In a disease followed over years, the record of what was given and what it achieved is the most useful document you can hold.

Can treatment be shared between China and my home country?

Yes, and for many patients that is how it works. The initial assessment and the intensive phases are usually done in China, and maintenance treatment is then taken at home with blood tests sent to us at defined intervals — which is how most patients manage a condition that requires years rather than weeks of treatment. Anything requiring an examination, a marrow procedure, an infusion or a transplant has to be done in person. Ask for the monitoring schedule in writing, including which results should be sent and how often, so that the local team and ours are working from the same plan.

What if the myeloma does not respond, or comes back?

There is usually a defined next step, and it depends on what has already been given and how long the response lasted. A further combination is used, generally making use of a class not yet tried or one that has been off treatment for an interval. For disease that has returned after several lines, a bispecific antibody directed at BCMA or CAR T-cell therapy is an option, subject to an assessment. Where a particular chromosome rearrangement is present, a targeted drug may be considered. Clinical trials are also a reasonable option at any line, and the treatment history is the information that determines what is sensible next.

Ask before you commit to a treatment plan

Send the protein studies with their values, the light chain ratio, the marrow reports with the chromosome findings, the imaging report, the treatment already given and the latest blood and kidney results. Our international patient team will return a written assessment within 48 hours of the file being complete, with an itemised estimate on request.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*